Scholarlink

<p>The article provides a review of cell therapy strategies for type 1 diabetes mellitus that are closest to approval by regulatory authorities and implementation in clinical practice. The data from contemporary clinical trials studying the safety and efficacy of cell technologies in the treatment of type 1 diabetes mellitus are presented. The main approaches to replacement and immunomodulatory cell therapy are defined. The results of using insulin-producing cells, regulatory T lymphocytes, tolerogenic dendritic cells, and mesenchymal stromal cells are described. Non-pharmacological strategies for preventing the rejection of allogeneic cell products are considered. The limitations and possibilities of cell therapy strategies for type 1 diabetes mellitus are analyzed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cell Therapy for Type 1 Diabetes Mellitus: a Review of Clinical Trials

  • 期刊论文

  • 发表日期：

    2025年5月1日

查看全文
  • M. I. Danilevskii,
  • O. V. Zakharova,
  • N. N. Skaletskiy,
  • Yu. B. Basok,
  • S. A. Roumiantsev,
  • A. V. Lyundup

摘要

The article provides a review of cell therapy strategies for type 1 diabetes mellitus that are closest to approval by regulatory authorities and implementation in clinical practice. The data from contemporary clinical trials studying the safety and efficacy of cell technologies in the treatment of type 1 diabetes mellitus are presented. The main approaches to replacement and immunomodulatory cell therapy are defined. The results of using insulin-producing cells, regulatory T lymphocytes, tolerogenic dendritic cells, and mesenchymal stromal cells are described. Non-pharmacological strategies for preventing the rejection of allogeneic cell products are considered. The limitations and possibilities of cell therapy strategies for type 1 diabetes mellitus are analyzed.